Compared to RT/anti-PD1 treatment, blood samples from triple-treated mice showed a more than 150-fold increase in CXCR3+ tumor-specific CD8+ T cells (Fig. 5c and Supplementary Fig. 9b). This evidence concerns the gene CD8A and neoplasm.